Vivos Therapeutics to Exchange Up to $4.5M Debt for Equity to Avoid Nasdaq Delisting
VVOS sits 50% above its 52-week low of $0.545 on light trading volume (0.2× avg).
Summary
Vivos Therapeutics announced a binding agreement with its senior lender, Streeterville Capital, to convert up to $4.5 million of outstanding debt into a combination of preferred and common stock. This action directly addresses the Nasdaq non-compliance notice received on April 22nd and the 'going concern' warning reiterated in the Q1 2026 10-Q on May 20th, both citing negative stockholders' equity and delisting risk. The exchange is intended to improve the company's stockholders' equity to meet Nasdaq listing standards and reduce debt service obligations, supporting cash flow and liquidity. Streeterville also committed to suspend debt repayments for 90 days. The agreement is contingent on Vivos completing one or more qualifying equity financings.
At the time of this announcement, VVOS was trading at $0.82 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $9.6M. The 52-week trading range was $0.55 to $7.95. This news item was assessed with positive market sentiment and an importance score of 9 out of 10. Source: GlobeNewswire.